Independent · evidence-based · non-judgmentalDraft · pending medical review
Not yet medically reviewed — information on this site is in preparation and has not been verified by a medical reviewer.
Drug index / Empathogen / MDA
Empathogen

MDA

1-(1,3-benzodioxol-5-yl)propan-2-amine

MDA (sassafras) is a psychedelic amphetamine closely related to MDMA, producing similar euphoria and empathogenic effects but with stronger psychedelic and stimulant properties and greater neurotoxicity risk. It is a Schedule I controlled substance in the US, and illicit supply is subject to fentanyl and misrepresentation risk.

Overview

MDA (3,4-methylenedioxyamphetamine) is a psychoactive drug of the amphetamine and phenethylamine families, closely related to MDMA. It is both an entactogen (producing emotional openness and empathy) and a psychedelic stimulant, and is sometimes sold as or mistaken for MDMA. It is also a metabolite of MDMA, meaning the body converts some MDMA into MDA.

Source: DEA; peer-reviewed literature (NIH/PMC); Wikipedia (CC-BY-SA)

Chemistry & mechanism of action

MDA increases release of serotonin, dopamine, and norepinephrine and blocks their reuptake, raising their levels in the brain, which produces its stimulant and empathogenic effects. It also has direct activity at serotonin receptors, giving it more pronounced psychedelic effects than MDMA. This heavy serotonin release underlies both the acute effects and the concern about serotonergic neurotoxicity.

Source: peer-reviewed literature (NIH/PMC); DEA

Effects

Effects overlap with MDMA — euphoria, emotional warmth, empathy, energy, and heightened senses — but MDA is generally described as more stimulating and more psychedelic, with more visual effects and a longer duration. Physical effects include raised heart rate and blood pressure, jaw clenching, dilated pupils, and reduced appetite, followed by a comedown with low mood and fatigue.

Source: peer-reviewed literature (NIH/PMC); DEA

Risks & harms

MDA shares MDMA's acute dangers and is thought to carry greater neurotoxic risk. Heavy serotonin and dopamine release strains the cardiovascular system (raised heart rate and blood pressure) and can cause dangerous overheating (hyperthermia), especially with physical exertion in hot environments, and water imbalance — both too little and, dangerously, too much water intake leading to hyponatremia. Combining MDA with other serotonergic drugs — SSRIs, MAOIs, other stimulants, or other empathogens — raises the risk of serotonin syndrome, a potentially fatal reaction with high fever, rigidity, agitation, and rapid heart rate. Longer, more stimulating experiences increase the strain. A critical contamination hazard applies to the illicit supply: substances sold as MDA or MDMA are frequently adulterated or entirely different, and pills and powders in this market have been found to contain illicitly manufactured fentanyl, which can cause fatal respiratory depression. There is no way to confirm identity or dose by eye. Anyone with a very high temperature, seizures, chest pain, collapse, or a severe psychiatric crisis needs emergency care — call 911, and Poison Control at 1-800-222-1222 can advise. This page has not yet been medically reviewed.

Source: DEA; SAMHSA; peer-reviewed literature (NIH/PMC)

Images

Visual references coming soon.

If it’s too intense

If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.

  • Get to a calm, safe space with someone you trust who is sober and can stay with you.
  • Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
  • Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
  • Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
  • A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
  • Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.

After MDMA, overheating and over-hydration are both dangerous: cool down, and sip to thirst rather than gulping water (forcing plain water can drop your blood sodium dangerously).

Call 911 (or Poison Control, 1-800-222-1222) right away for chest pain, a very high body temperature, a seizure, unconsciousness, or severe confusion. These are medical emergencies, not something to wait out.

Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.

Forensic dossier

Draft · every field is source-cited or marked “Unknown — pending review”

Identity

IUPAC name
1-(1,3-benzodioxol-5-yl)propan-2-aminePubChem PUG-REST · retrieved 2026-06-18
SMILES
CC(CC1=CC2=C(C=C1)OCO2)NPubChem PUG-REST · retrieved 2026-06-18
InChIKey
NGBBVGZWCFBOGO-UHFFFAOYSA-NPubChem PUG-REST · retrieved 2026-06-18
Synonyms / aliases
sass, sally, Tenamfetamine, 3,4-methylenedioxyamphetamine, Methylenedioxyamphetamine, Tenamfetaminum, Love, methylene dioxyamphetamine, Tenanfetamina, 3,4 Methylenedioxyamphetamine, 3,4-Methylenedioxy-amphetamine, MDA (pharmaceutical)PubChem PUG-REST + seed aliases · retrieved 2026-06-18

Composition

Composition
N/A — single compound (see Identity)

Physical / pill characteristics

Dosage form
Unknown — pending review
Route
Unknown — pending review
Shape
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Color
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Imprint
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Score
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)

Scheduling & legal status

US schedule
Unknown — pending review
International
Unknown — pending review

Dosage

Pending medical reviewer

Sources

← Back to the drug index